TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred StockGlobeNewsWire • 04/03/23
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic CancerGlobeNewsWire • 02/28/23
TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatmentGlobeNewsWire • 02/22/23
TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 02/17/23
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 02/16/23
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in MelanomaGlobeNewsWire • 01/31/23
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical TrialGlobeNewsWire • 12/29/22
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid TumorsGlobeNewsWire • 11/30/22
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business UpdateGlobeNewsWire • 11/14/22
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic AdenocarcinomaGlobeNewsWire • 11/09/22
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic AdenocarcinomaGlobeNewsWire • 10/26/22
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in OncologyGlobeNewsWire • 10/13/22
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/27/22